{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T01:06:19Z","timestamp":1795136779041,"version":"4.10.3"},"reference-count":104,"publisher":"Bentham Science Publishers Ltd.","issue":"17","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2020,1,24]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The JAK-STAT pathway is an important physiologic regulator of different cellular functions including\nproliferation, apoptosis, differentiation, and immunological responses. Out of six different STAT proteins,\nSTAT5 plays its main role in hematopoiesis and constitutive STAT5 activation seems to be a key event in the\npathogenesis of several hematological malignancies. This has led many researchers to develop compounds capable\nof inhibiting STAT5 activation or interfering with its functions. Several anti-STAT5 molecules have\nshown potent STAT5 inhibitory activity in vitro. However, compared to the large amount of clinical studies with\nJAK inhibitors that are currently widely used in the clinics to treat myeloproliferative disorders, the clinical\ntrials with STAT5 inhibitors are very limited. At present, a few STAT5 inhibitors are in phase I or II clinical\ntrials for the treatment of leukemias and graft vs host disease. These studies seem to indicate that such compounds\ncould be well tolerated and useful in reducing the occurrence of resistance to tyrosine kinase inhibitors\nin chronic myeloid leukemia. Of interest, STAT5 seems to play an important role in the regulation of hematopoietic\nstem cell self-renewal suggesting that combination therapies including STAT5 inhibitors can erode the\ncancer stem cell pool and possibly open the way for the complete cancer eradication. In this review, we discuss the\nimplication of STAT5 in hematological malignancies and the results obtained with the novel STAT5 inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1871520619666190906160848","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T01:20:57Z","timestamp":1567819257000},"page":"2036-2046","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["STAT5 and STAT5 Inhibitors in Hematological Malignancies"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7974-2319","authenticated-orcid":true,"given":"Manlio","family":"Tolomeo","sequence":"first","affiliation":[{"name":"Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5168-2676","authenticated-orcid":true,"given":"Maria","family":"Meli","sequence":"additional","affiliation":[{"name":"Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Grimaudo","sequence":"additional","affiliation":[{"name":"Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7840","DOI":"10.1073\/pnas.89.16.7840","volume":"89","author":"Fu X.Y.","year":"1992","unstructured":"Fu X.Y.; Schindler C.; Improta T.; Aebersold R.; Darnell J.E.; The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci USA 1992,89(16),7840-7843","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"7836","DOI":"10.1073\/pnas.89.16.7836","volume":"89","author":"Schindler C.","year":"1992","unstructured":"Schindler C.; Fu X.Y.; Improta T.; Aebersold R.; Darnell J.E.; Proteins of transcription factor ISGF-3: One gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci USA 1992,89(16),7836-7839","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1126\/science.1496401","volume":"257","author":"Schindler C.","year":"1992","unstructured":"Schindler C.; Shuai K.; Prezioso V.R.; Darnell J.E.; Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 1992,257(5071),809-813","journal-title":"Science"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0962-8924(99)01709-2","volume":"10","author":"Chatterjee-Kishore M.","year":"2000","unstructured":"Chatterjee-Kishore M.; van den Akker F.; Stark G.R.; Association of STATs with relatives and friends. Trends Cell Biol 2000,10(3),106-111","journal-title":"Trends Cell Biol"},{"key":"ref=5","first-page":"395","volume":"17","author":"Abroun S.","year":"2015","unstructured":"Abroun S.; Saki N.; Ahmadvand M.; Asghari F.; Salari F.; Rahim F.; STATs: An old story, yet mesmerizing. Cell J 2015,17(3),395-411","journal-title":"Cell J"},{"key":"ref=6","first-page":"104","volume":"1815","author":"Ferbeyre G.","year":"2011","unstructured":"Ferbeyre G.; Moriggl R.; The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta 2011,1815(1),104-114","journal-title":"Biochim Biophys Acta"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1039\/b606246f","volume":"2","author":"Lim C.P.","year":"2006","unstructured":"Lim C.P.; Cao X.; Structure, function, and regulation of STAT proteins. Mol Biosyst 2006,2(11),536-550","journal-title":"Mol Biosyst"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"6675","DOI":"10.1074\/jbc.M001748200","volume":"276","author":"Ehret G.B.","year":"2001","unstructured":"Ehret G.B.; Reichenbach P.; Schindler U.; Horvath C.M.; Fritz S.; Nabholz M.; Bucher P.; DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J Biol Chem 2001,276(9),6675-6688","journal-title":"J Biol Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3181\/00379727-206-43757","volume":"206","author":"Ihle J.N.","year":"1994","unstructured":"Ihle J.N.; The Janus kinase family and signaling through members of the cytokine receptor superfamily. Proc Soc Exp Biol Med 1994,206(3),268-272","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"Darnell J.E.","year":"1994","unstructured":"Darnell J.E.; Kerr I.M.; Stark G.R.; Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994,264(5164),1415-1421","journal-title":"Science"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","volume":"5","author":"Yamaoka K.","year":"2004","unstructured":"Yamaoka K.; Saharinen P.; Pesu M.; Holt V.E.T.; Silvennoinen O.; O\u2019Shea J.J.; The Janus kinases (Jaks). Genome Biol 2004,5(12),253","journal-title":"Genome Biol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.immunol.24.021605.090616","volume":"27","author":"Wang X.","year":"2009","unstructured":"Wang X.; Lupardus P.; Laporte S.L.; Garcia K.C.; Structural biology of shared cytokine receptors. Annu Rev Immunol 2009,27(1),29-60","journal-title":"Annu Rev Immunol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/1947601910397187","volume":"1","author":"Jatiani S.S.","year":"2010","unstructured":"Jatiani S.S.; Baker S.J.; Silverman L.R.; Reddy E.P.; Jak\/STAT pathways in cytokine signaling and myeloproliferative disorders: Approaches for targeted therapies. Genes Cancer 2010,1(10),979-993","journal-title":"Genes Cancer"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/0092-8674(94)90357-3","volume":"76","author":"Shuai K.","year":"1994","unstructured":"Shuai K.; Horvath C.M.; Huang L.H.; Qureshi S.A.; Cowburn D.; Darnell J.E.; Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994,76(5),821-828","journal-title":"Cell"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1006\/bbrc.1998.8829","volume":"247","author":"Novak U.","year":"1998","unstructured":"Novak U.; Ji H.; Kanagasundaram V.; Simpson R.; Paradiso L.; STAT3 forms stable homodimers in the presence of divalent cations prior to activation. Biochem Biophys Res Commun 1998,247(3),558-563","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41375-018-0117-x","volume":"32","author":"Wingelhofer B.","year":"2018","unstructured":"Wingelhofer B.; Neubauer H.A.; Valent P.; Han X.; Constantinescu S.N.; Gunning P.T.; M\u00fcller M.; Moriggl R.; Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia 2018,32(8),1713-1726","journal-title":"Leukemia"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/bjc.2015.233","volume":"113","author":"Thomas S.J.","year":"2015","unstructured":"Thomas S.J.; Snowden J.A.; Zeidler M.P.; Danson S.J.; The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer 2015,113(3),365-371","journal-title":"Br J Cancer"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cyto.2016.06.017","volume":"87","author":"Pencik J.","year":"2016","unstructured":"Pencik J.; Pham H.T.T.; Schmoellerl J.; Javaheri T.; Schlederer M.; Culig Z.; Merkel O.; Moriggl R.; Grebien F.; Kenner L.; JAK-STAT signaling in cancer: From cytokines to non-coding genome. Cytokine 2016,87,26-36","journal-title":"Cytokine"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2017.05.033","volume":"451","author":"Groner B.","year":"2017","unstructured":"Groner B.; von Manstein V.; Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol 2017,451,1-14","journal-title":"Mol Cell Endocrinol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/blood-2013-02-485573","volume":"122","author":"Warsch W.","year":"2013","unstructured":"Warsch W.; Walz C.; Sexl V.; JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood 2013,122(13),2167-2175","journal-title":"Blood"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1600-0609.2012.01825.x","volume":"89","author":"Brady A.","year":"2012","unstructured":"Brady A.; Gibson S.; Rybicki L.; Hsi E.; Saunthararajah Y.; Sekeres M.A.; Tiu R.; Copelan E.; Kalaycio M.; Sobecks R.; Bates J.; Advani A.S.; Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia. Eur J Haematol 2012,89(4),288-293","journal-title":"Eur J Haematol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1128\/MCB.11.7.3745","volume":"11","author":"Schmitt-Ney M.","year":"1991","unstructured":"Schmitt-Ney M.; Doppler W.; Ball R.K.; Groner B.; Beta-casein gene promoter activity is regulated by the hormone-mediated relief of transcriptional repression and a mammary-gland-specific nuclear factor. Mol Cell Biol 1991,11(7),3745-3755","journal-title":"Mol Cell Biol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1101\/gad.1643908","volume":"22","author":"Hennighausen L.","year":"2008","unstructured":"Hennighausen L.; Robinson G.W.; Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 2008,22(6),711-721","journal-title":"Genes Dev"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148308","volume":"11","author":"Oshida K.","year":"2016","unstructured":"Oshida K.; Vasani N.; Waxman D.J.; Corton J.C.; Disruption of STAT5b-regulated sexual dimorphism of the liver transcriptome by diverse factors is a common event. PLoS One 2016,11(3)","journal-title":"PLoS One"},{"key":"ref=25","first-page":"795","volume":"9","author":"Liu X.","year":"1998","unstructured":"Liu X.; Gallego M.I.; Smith G.H.; Robinson G.W.; Hennighausen L.; Functional rescue of Stat5a-null mammary tissue through the activation of compensating signals including Stat5b. Cell Growth Differ 1998,9(9),795-803","journal-title":"Cell Growth Differ"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/blood-2005-09-3596","volume":"107","author":"Hoelbl A.","year":"2006","unstructured":"Hoelbl A.; Kovacic B.; Kerenyi M.A.; Simma O.; Warsch W.; Cui Y.; Beug H.; Hennighausen L.; Moriggl R.; Sexl V.; Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 2006,107(12),4898-4906","journal-title":"Blood"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"30977","DOI":"10.1038\/srep30977","volume":"6","author":"Lee J.","year":"2016","unstructured":"Lee J.; Seong S.; Kim J.H.; Kim K.; Kim I.; Jeong B-C.; Nam K-I.; Kim K.K.; Hennighausen L.; Kim N.; STAT5 is a key transcription factor for IL-3-mediated inhibition of RANKL-induced osteoclastogenesis. Sci Rep 2016,6(1),30977","journal-title":"Sci Rep"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.immuni.2013.02.011","volume":"38","author":"Wan C-K.","year":"2013","unstructured":"Wan C-K.; Oh J.; Li P.; West E.E.; Wong E.A.; Andraski A.B.; Spolski R.; Yu Z-X.; He J.; Kelsall B.L.; Leonard W.J.; The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 2013,38(3),514-527","journal-title":"Immunity"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/ijc.20484","volume":"112","author":"Iavnilovitch E.","year":"2004","unstructured":"Iavnilovitch E.; Cardiff R.D.; Groner B.; Barash I.; Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer 2004,112(4),607-619","journal-title":"Int J Cancer"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/oby.2011.66","volume":"19","author":"Stewart W.C.","year":"2011","unstructured":"Stewart W.C.; Pearcy L.A.; Floyd Z.E.; Stephens J.M.; STAT5A expression in Swiss 3T3 cells promotes adipogenesis in vivo in an athymic mice model system. Obesity (Silver Spring) 2011,19(9),1731-1734","journal-title":"Obesity (Silver Spring)"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cellsig.2015.09.010","volume":"27","author":"Gao P.","year":"2015","unstructured":"Gao P.; Zhang Y.; Liu Y.; Chen J.; Zong C.; Yu C.; Cui S.; Gao W.; Qin D.; Sun W.; Li X.; Wang X.; Signal transducer and activator of transcription 5B (STAT5B) modulates adipocyte differentiation via MOF. Cell Signal 2015,27(12),2434-2443","journal-title":"Cell Signal"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cytogfr.2004.09.001","volume":"15","author":"Paukku K.","year":"2004","unstructured":"Paukku K.; Silvennoinen O.; STATs as critical mediators of signal transduction and transcription: Lessons learned from STAT5. Cytokine Growth Factor Rev 2004,15(6),435-455","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.2741\/2274","volume":"12","author":"Bunting K.D.","year":"2007","unstructured":"Bunting K.D.; STAT5 signaling in normal and pathologic hematopoiesis. Front Biosci 2007,12,2807-2820","journal-title":"Front Biosci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"15942","DOI":"10.1074\/jbc.270.27.15942","volume":"270","author":"Pallard C.","year":"1995","unstructured":"Pallard C.; Gouilleux F.; Charon M.; Groner B.; Gisselbrecht S.; Dusanter-Fourt I.; Interleukin-3, erythropoietin, and prolactin activate a STAT5-like factor in lymphoid cells. J Biol Chem 1995,270(27),15942-15945","journal-title":"J Biol Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.bi.64.070195.003201","volume":"64","author":"Schindler C.","year":"1995","unstructured":"Schindler C.; Darnell J.E.; Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. Annu Rev Biochem 1995,64(1),621-651","journal-title":"Annu Rev Biochem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1089\/scd.2005.14.505","volume":"14","author":"Feugier P.","year":"2005","unstructured":"Feugier P.; Li N.; Jo D.Y.; Shieh J.H.; MacKenzie K.L.; Lesesve J.F.; Latger-Cannard V.; Bensoussan D.; Crystal R.G.; Rafii S.; Stoltz J.F.; Moore M.A.; Osteopetrotic mouse stroma with thrombopoietin, c-kit ligand, and flk-2 ligand supports long-term mobilized CD34+ hematopoiesis in vitro. Stem Cells Dev 2005,14(5),505-516","journal-title":"Stem Cells Dev"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1182\/blood.V99.2.479","volume":"99","author":"Bunting K.D.","year":"2002","unstructured":"Bunting K.D.; Bradley H.L.; Hawley T.S.; Moriggl R.; Sorrentino B.P.; Ihle J.N.; Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood 2002,99(2),479-487","journal-title":"Blood"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1182\/blood-2008-09-181107","volume":"113","author":"Wang Z.","year":"2009","unstructured":"Wang Z.; Li G.; Tse W.; Bunting K.D.; Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood 2009,113(20),4856-4865","journal-title":"Blood"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","volume":"107","author":"Ye D.","year":"2006","unstructured":"Ye D.; Wolff N.; Li L.; Zhang S.; Ilaria R.L.; STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 2006,107(12),4917-4925","journal-title":"Blood"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","volume":"189","author":"Nieborowska-Skorska M.","year":"1999","unstructured":"Nieborowska-Skorska M.; Wasik M.A.; Slupianek A.; Salomoni P.; Kitamura T.; Calabretta B.; Skorski T.; Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis. J Exp Med 1999,189(8),1229-1242","journal-title":"J Exp Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/emmm.201000062","volume":"2","author":"Hoelbl A.","year":"2010","unstructured":"Hoelbl A.; Schuster C.; Kovacic B.; Zhu B.; Wickre M.; Hoelzl M.A.; Fajmann S.; Grebien F.; Warsch W.; Stengl G.; Hennighausen L.; Poli V.; Beug H.; Moriggl R.; Sexl V.; Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia. EMBO Mol Med 2010,2(3),98-110","journal-title":"EMBO Mol Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/sj.leu.2402317","volume":"15","author":"Birkenkamp K.U.","year":"2001","unstructured":"Birkenkamp K.U.; Geugien M.; Lemmink H.H.; Kruijer W.; Vellenga E.; Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 2001,15(12),1923-1931","journal-title":"Leukemia"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood.V87.5.1692.1692","volume":"87","author":"Gouilleux-Gruart V.","year":"1996","unstructured":"Gouilleux-Gruart V.; Gouilleux F.; Desaint C.; Claisse J.F.; Capiod J.C.; Delobel J.; Weber-Nordt R.; Dusanter-Fourt I.; Dreyfus F.; Groner B.; Prin L.; STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996,87(5),1692-1697","journal-title":"Blood"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0301-472X(01)00787-1","volume":"30","author":"Spiekermann K.","year":"2002","unstructured":"Spiekermann K.; Pau M.; Schwab R.; Schmieja K.; Franzrahe S.; Hiddemann W.; Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002,30(3),262-271","journal-title":"Exp Hematol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","volume":"108","author":"Lacout C.","year":"2006","unstructured":"Lacout C.; Pisani D.F.; Tulliez M.; Gachelin F.M.; Vainchenker W.; Villeval J-L.; JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006,108(5),1652-1660","journal-title":"Blood"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","volume":"107","author":"Wernig G.","year":"2006","unstructured":"Wernig G.; Mercher T.; Okabe R.; Levine R.L.; Lee B.H.; Gilliland D.G.; Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006,107(11),4274-4281","journal-title":"Blood"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"16792","DOI":"10.18632\/oncotarget.24698","volume":"9","author":"Simpson H.M.","year":"2018","unstructured":"Simpson H.M.; Furusawa A.; Sadashivaiah K.; Civin C.I.; Banerjee A.; STAT5 inhibition induces TRAIL\/DR4 dependent apoptosis in peripheral T-cell lymphoma. Oncotarget 2018,9(24),16792-16806","journal-title":"Oncotarget"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V96.6.2269","volume":"96","author":"Gesbert F.","year":"2000","unstructured":"Gesbert F.; Griffin J.D.; Bcr\/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000,96(6),2269-2276","journal-title":"Blood"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"8934","DOI":"10.1128\/MCB.23.24.8934-8945.2003","volume":"23","author":"Magn\u00e9 S.","year":"2003","unstructured":"Magn\u00e9 S.; Caron S.; Charon M.; Rouyez M-C.; Dusanter-Fourt I.; STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression. Mol Cell Biol 2003,23(24),8934-8945","journal-title":"Mol Cell Biol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1006\/mcbr.2000.0231","volume":"3","author":"de Groot R.P.","year":"2000","unstructured":"de Groot R.P.; Raaijmakers J.A.M.; Lammers J-W.J.; Koenderman L.; STAT5-dependent cyclinD1 and Bcl-XL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 2000,3(5),299-305","journal-title":"Mol Cell Biol Res Commun"},{"key":"ref=51","doi-asserted-by":"publisher","DOI":"10.4161\/23723548.2014.963450","volume":"1","author":"Ross T.S.","year":"2014","unstructured":"Ross T.S.; Mgbemena V.E.; Re-evaluating the role of BCR\/ABL in chronic myelogenous leukemia. Mol Cell Oncol 2014,1(3)","journal-title":"Mol Cell Oncol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"8547","DOI":"10.1038\/sj.onc.1206082","volume":"21","author":"Salesse S.","year":"2002","unstructured":"Salesse S.; Verfaillie C.M.; BCR\/ABL: From molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Oncogene 2002,21(56),8547-8559","journal-title":"Oncogene"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1177\/1078155217710553","volume":"24","author":"Cuellar S.","year":"2018","unstructured":"Cuellar S.; Vozniak M.; Rhodes J.; Forcello N.; Olszta D.; BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract 2018,24(6),433-452","journal-title":"J Oncol Pharm Pract"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/17474086.2018.1451322","volume":"11","author":"Massaro F.","year":"2018","unstructured":"Massaro F.; Colafigli G.; Molica M.; Breccia M.; Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: Safety and efficacy. Expert Rev Hematol 2018,11(4),301-306","journal-title":"Expert Rev Hematol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/10428194.2017.1379074","volume":"59","author":"Saglio G.","year":"2018","unstructured":"Saglio G.; Jabbour E.; First-line therapy for chronic phase CML: Selecting the optimal BCR-ABL1-targeted TKI. Leuk Lymphoma 2018,59(7),1523-1538","journal-title":"Leuk Lymphoma"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12185-018-2519-y","volume":"108","author":"Inoue A.","year":"2018","unstructured":"Inoue A.; Kobayashi C.I.; Shinohara H.; Miyamoto K.; Yamauchi N.; Yuda J.; Akao Y.; Minami Y.; Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence. Int J Hematol 2018,108(4),365-370","journal-title":"Int J Hematol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MOH.0000000000000403","volume":"25","author":"Talati C.","year":"2018","unstructured":"Talati C.; Pinilla-Ibarz J.; Resistance in chronic myeloid leukemia: Definitions and novel therapeutic agents. Curr Opin Hematol 2018,25(2),154-161","journal-title":"Curr Opin Hematol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.4161\/cc.25116","volume":"12","author":"Warsch W.","year":"2013","unstructured":"Warsch W.; Grundschober E.; Sexl V.; Adding a new facet to STAT5 in CML: Multitasking for leukemic cells. Cell Cycle 2013,12(12),1813-1814","journal-title":"Cell Cycle"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"Ilaria R.L.","year":"1996","unstructured":"Ilaria R.L.; Van Etten R.A.; P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996,271(49),31704-31710","journal-title":"J Biol Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1084\/jem.183.3.811","volume":"183","author":"Carlesso N.","year":"1996","unstructured":"Carlesso N.; Frank D.A.; Griffin J.D.; Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl. J Exp Med 1996,183(3),811-820","journal-title":"J Exp Med"},{"key":"ref=61","first-page":"1724","volume":"10","author":"Frank D.A.","year":"1996","unstructured":"Frank D.A.; Varticovski L.; BCR\/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 1996,10(11),1724-1730","journal-title":"Leukemia"},{"key":"ref=62","first-page":"247","volume":"13","author":"Shuai K.","year":"1996","unstructured":"Shuai K.; Halpern J.; ten Hoeve J.; Rao X.; Sawyers C.L.; Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996,13(2),247-254","journal-title":"Oncogene"},{"key":"ref=63","first-page":"58","volume":"3","author":"Kaymaz B.T.","year":"2013","unstructured":"Kaymaz B.T.; Selvi N.; Gokbulut A.A.; Aktan C.; G\u00fcnd\u00fcz C.; Saydam G.; Sahin F.; Cetinta\u015f V.B.; Baran Y.; Kosova B.; Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis. Am J Blood Res 2013,3(1),58-70","journal-title":"Am J Blood Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.3109\/10428194.2010.507830","volume":"51","author":"Kosova B.","year":"2010","unstructured":"Kosova B.; Tezcanli B.; Ekiz H.A.; Cakir Z.; Selvi N.; Dalmizrak A.; Kartal M.; Gunduz U.; Baran Y.; Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leuk Lymphoma 2010,51(10),1895-1901","journal-title":"Leuk Lymphoma"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","volume":"117","author":"Warsch W.","year":"2011","unstructured":"Warsch W.; Kollmann K.; Eckelhart E.; Fajmann S.; Cerny-Reiterer S.; H\u00f6lbl A.; Gleixner K.V.; Dworzak M.; Mayerhofer M.; Hoermann G.; Herrmann H.; Sillaber C.; Egger G.; Valent P.; Moriggl R.; Sexl V.; High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011,117(12),3409-3420","journal-title":"Blood"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"Papaemmanuil E.","year":"2016","unstructured":"Papaemmanuil E.; Gerstung M.; Bullinger L.; Gaidzik V.I.; Paschka P.; Roberts N.D.; Potter N.E.; Heuser M.; Thol F.; Bolli N.; Gundem G.; Van Loo P.; Martincorena I.; Ganly P.; Mudie L.; McLaren S.; O\u2019Meara S.; Raine K.; Jones D.R.; Teague J.W.; Butler A.P.; Greaves M.F.; Ganser A.; D\u00f6hner K.; Schlenk R.F.; D\u00f6hner H.; Campbell P.J.; Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016,374(23),2209-2221","journal-title":"N Engl J Med"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1532\/IJH97.05090","volume":"82","author":"Choudhary C.","year":"2005","unstructured":"Choudhary C.; M\u00fcller-Tidow C.; Berdel W.E.; Serve H.; Signal transduction of oncogenic Flt3. Int J Hematol 2005,82(2),93-99","journal-title":"Int J Hematol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.2174\/1381612043384394","volume":"10","author":"Schmidt-Arras D.","year":"2004","unstructured":"Schmidt-Arras D.; Schw\u00e4ble J.; B\u00f6hmer F.D.; Serve H.; Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr Pharm Des 2004,10(16),1867-1883","journal-title":"Curr Pharm Des"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.3324\/haematol.2016.157180","volume":"102","author":"Fischer M.","year":"2017","unstructured":"Fischer M.; Schnetzke U.; Spies-Weisshart B.; Walther M.; Fleischmann M.; Hilgendorf I.; Hochhaus A.; Scholl S.; Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia. Haematologica 2017,102(4),e129-e131","journal-title":"Haematologica"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"Gilliland D.G.","year":"2002","unstructured":"Gilliland D.G.; Griffin J.D.; The roles of FLT3 in hematopoiesis and leukemia. Blood 2002,100(5),1532-1542","journal-title":"Blood"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejmech.2019.05.021","volume":"176","author":"Heng H.","year":"2019","unstructured":"Heng H.; Wang Z.; Li H.; Huang Y.; Lan Q.; Guo X.; Zhang L.; Zhi Y.; Cai J.; Qin T.; Xiang L.; Wang S.; Chen Y.; Lu T.; Lu S.; Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model. Eur J Med Chem 2019,176(176),248-267","journal-title":"Eur J Med Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.2147\/OTT.S171640","volume":"11","author":"Sutamtewagul G.","year":"2018","unstructured":"Sutamtewagul G.; Vigil C.E.; Clinical use of FLT3 inhibitors in acute myeloid leukemia. OncoTargets Ther 2018,11(1),7041-7052","journal-title":"OncoTargets Ther"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00292-016-0240-2","volume":"37","author":"Mullally A.","year":"2016","unstructured":"Mullally A.; Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms. Pathologe 2016,37(Suppl. 2),175-179","journal-title":"Pathologe"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"Levine R.L.","year":"2005","unstructured":"Levine R.L.; Wadleigh M.; Cools J.; Ebert B.L.; Wernig G.; Huntly B.J.P.; Boggon T.J.; Wlodarska I.; Clark J.J.; Moore S.; Adelsperger J.; Koo S.; Lee J.C.; Gabriel S.; Mercher T.; D\u2019Andrea A.; Fr\u00f6hling S.; D\u00f6hner K.; Marynen P.; Vandenberghe P.; Mesa R.A.; Tefferi A.; Griffin J.D.; Eck M.J.; Sellers W.R.; Meyerson M.; Golub T.R.; Lee S.J.; Gilliland D.G.; Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005,7(4),387-397","journal-title":"Cancer Cell"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.blre.2016.11.001","volume":"31","author":"Grinfeld J.","year":"2017","unstructured":"Grinfeld J.; Godfrey A.L.; After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera. Blood Rev 2017,31(3),101-118","journal-title":"Blood Rev"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s12094-017-1618-1","volume":"19","author":"Saki N.","year":"2017","unstructured":"Saki N.; Shirzad R.; Rahim F.; Saki Malehi A.; Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2 mutations and laboratory findings: A meta-analysis. Clin Transl Oncol 2017,19(7),874-883","journal-title":"Clin Transl Oncol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"Baxter E.J.","year":"2005","unstructured":"Baxter E.J.; Scott L.M.; Campbell P.J.; East C.; Fourouclas N.; Swanton S.; Vassiliou G.S.; Bench A.J.; Boyd E.M.; Curtin N.; Scott M.A.; Erber W.N.; Green A.R.; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005,365(9464),1054-1061","journal-title":"Lancet"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1182\/blood-2011-03-345215","volume":"119","author":"Yan D.","year":"2012","unstructured":"Yan D.; Hutchison R.E.; Mohi G.; Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2012,119(15),3539-3549","journal-title":"Blood"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/CBM-140434","volume":"15","author":"Sonkin D.","year":"2015","unstructured":"Sonkin D.; Palmer M.; Rong X.; Horrigan K.; Regnier C.H.; Fanton C.; Holash J.; Pinzon-Ortiz M.; Squires M.; Sirulnik A.; Radimerski T.; Schlegel R.; Morrissey M.; Cao Z.A.; The identification and characterization of a STAT5 gene signature in hematologic malignancies. Cancer Biomark 2015,15(1),79-87","journal-title":"Cancer Biomark"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"Holyoake T.L.","year":"2017","unstructured":"Holyoake T.L.; Vetrie D.; The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 2017,129(12),1595-1606","journal-title":"Blood"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"Corbin A.S.","year":"2011","unstructured":"Corbin A.S.; Agarwal A.; Loriaux M.; Cortes J.; Deininger M.W.; Druker B.J.; Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011,121(1),396-409","journal-title":"J Clin Invest"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"Graham S.M.","year":"2002","unstructured":"Graham S.M.; J\u00f8rgensen H.G.; Allan E.; Pearson C.; Alcorn M.J.; Richmond L.; Holyoake T.L.; Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002,99(1),319-325","journal-title":"Blood"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"J\u00f8rgensen H.G.","year":"2007","unstructured":"J\u00f8rgensen H.G.; Allan E.K.; Jordanides N.E.; Mountford J.C.; Holyoake T.L.; Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007,109(9),4016-4019","journal-title":"Blood"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","volume":"117","author":"Nelson E.A.","year":"2011","unstructured":"Nelson E.A.; Walker S.R.; Weisberg E.; Bar-Natan M.; Barrett R.; Gashin L.B.; Terrell S.; Klitgaard J.L.; Santo L.; Addorio M.R.; Ebert B.L.; Griffin J.D.; Frank D.A.; The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011,117(12),3421-3429","journal-title":"Blood"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"Prost S.","year":"2015","unstructured":"Prost S.; Relouzat F.; Spentchian M.; Ouzegdouh Y.; Saliba J.; Massonnet G.; Beressi J-P.; Verhoeyen E.; Raggueneau V.; Maneglier B.; Castaigne S.; Chomienne C.; Chr\u00e9tien S.; Rousselot P.; Leboulch P.; Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists. Nature 2015,525(7569),380-383","journal-title":"Nature"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/cbic.200700701","volume":"9","author":"M\u00fcller J.","year":"2008","unstructured":"M\u00fcller J.; Sperl B.; Reindl W.; Kiessling A.; Berg T.; Discovery of chromone-based inhibitors of the transcription factor STAT5. ChemBioChem 2008,9(5),723-727","journal-title":"ChemBioChem"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1016\/j.bmcl.2014.07.069","volume":"24","author":"Rondanin R.","year":"2014","unstructured":"Rondanin R.; Simoni D.; Romagnoli R.; Baruchello R.; Marchetti P.; Costantini C.; Fochi S.; Padroni G.; Grimaudo S.; Pipitone R.M.; Meli M.; Tolomeo M.; Inhibition of activated STAT5 in Bcr\/Abl expressing leukemia cells with new pimozide derivatives. Bioorg Med Chem Lett 2014,24(18),4568-4574","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/cmdc.201700234","volume":"12","author":"Rondanin R.","year":"2017","unstructured":"Rondanin R.; Simoni D.; Maccesi M.; Romagnoli R.; Grimaudo S.; Pipitone R.M.; Meli M.; Cascio A.; Tolomeo M.; Effects of pimozide derivatives on pSTAT5 in K562 cells. ChemMedChem 2017,12(15),1183-1190","journal-title":"ChemMedChem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/CAD.0b013e32835e64a0","volume":"24","author":"Grimaudo S.","year":"2013","unstructured":"Grimaudo S.; Meli M.; Di Cristina A.; Ferro A.; Pipitone M.R.; Romagnoli R.; Simoni D.; Dieli F.; Tolomeo M.; The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells. Anticancer Drugs 2013,24(4),384-393","journal-title":"Anticancer Drugs"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejmech.2015.11.022","volume":"108","author":"Romagnoli R.","year":"2016","unstructured":"Romagnoli R.; Baraldi P.G.; Prencipe F.; Lopez-Cara C.; Rondanin R.; Simoni D.; Hamel E.; Grimaudo S.; Pipitone R.M.; Meli M.; Tolomeo M.; Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation. Eur J Med Chem 2016,108(108),39-52","journal-title":"Eur J Med Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/jm200720n","volume":"55","author":"Page B.D.G.","year":"2012","unstructured":"Page B.D.G.; Khoury H.; Laister R.C.; Fletcher S.; Vellozo M.; Manzoli A.; Yue P.; Turkson J.; Minden M.D.; Gunning P.T.; Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem 2012,55(3),1047-1055","journal-title":"J Med Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1021\/ml500165r","volume":"5","author":"Cumaraswamy A.A.","year":"2014","unstructured":"Cumaraswamy A.A.; Lewis A.M.; Geletu M.; Todic A.; Diaz D.B.; Cheng X.R.; Brown C.E.; Laister R.C.; Muench D.; Kerman K.; Grimes H.L.; Minden M.D.; Gunning P.T.; Nanomolar-Potency small molecule inhibitor of STAT5 protein. ACS Med Chem Lett 2014,5(11),1202-1206","journal-title":"ACS Med Chem Lett"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/1535-7163.MCT-14-0883","volume":"14","author":"Liao Z.","year":"2015","unstructured":"Liao Z.; Gu L.; Vergalli J.; Mariani S.A.; De Dominici M.; Lokareddy R.K.; Dagvadorj A.; Purushottamachar P.; McCue P.A.; Trabulsi E.; Lallas C.D.; Gupta S.; Ellsworth E.; Blackmon S.; Ertel A.; Fortina P.; Leiby B.; Xia G.; Rui H.; Hoang D.T.; Gomella L.G.; Cingolani G.; Njar V.; Pattabiraman N.; Calabretta B.; Nevalainen M.T.; Structure-based screen identifies a potent small molecule inhibitor of Stat5a\/b with therapeutic potential for prostate cancer and chronic myeloid leukemia. Mol Cancer Ther 2015,14(8),1777-1793","journal-title":"Mol Cancer Ther"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1089\/dna.2010.1112","volume":"30","author":"Wang X.","year":"2011","unstructured":"Wang X.; Zeng J.; Shi M.; Zhao S.; Bai W.; Cao W.; Tu Z.; Huang Z.; Feng W.; Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth. DNA Cell Biol 2011,30(2),71-78","journal-title":"DNA Cell Biol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00277-012-1575-2","volume":"92","author":"Kaymaz B.T.","year":"2013","unstructured":"Kaymaz B.T.; Selvi N.; G\u00fcnd\u00fcz C.; Aktan C.; Dalm\u0131zrak A.; Saydam G.; Kosova B.; Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis. Ann Hematol 2013,92(2),151-162","journal-title":"Ann Hematol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.3892\/mmr.2015.3298","volume":"11","author":"Wu L.","year":"2015","unstructured":"Wu L.; Li Y.; Fan J-M.; Zhang Z-M.; Ouyang J-L.; Ni T-T.; Wu H-X.; Li H.; MicroRNA-204 targets signal transducer and activator of transcription 5 expression and inhibits proliferation of B-cell lymphoma cells. Mol Med Rep 2015,11(6),4567-4572","journal-title":"Mol Med Rep"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/1535-7163.MCT-13-0341","volume":"13","author":"Liu S.","year":"2014","unstructured":"Liu S.; Walker S.R.; Nelson E.A.; Cerulli R.; Xiang M.; Toniolo P.A.; Qi J.; Stone R.M.; Wadleigh M.; Bradner J.E.; Frank D.A.; Targeting STAT5 in hematologic malignancies through inhibition of the Bromodomain and Extra-Terminal (BET) bromodomain protein BRD2. Mol Cancer Ther 2014,13(5),1194-1205","journal-title":"Mol Cancer Ther"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"36044","DOI":"10.1038\/srep36044","volume":"6","author":"Liu L-J.","year":"2016","unstructured":"Liu L-J.; Wang W.; Kang T-S.; Liang J-X.; Liu C.; Kwong D.W.J.; Wong V.K.W.; Ma D-L.; Leung C-H.; Antagonizing STAT5B dimerization with an osmium complex. Sci Rep 2016,6(1),36044","journal-title":"Sci Rep"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41598-017-00920-3","volume":"7","author":"Elumalai N.","year":"2017","unstructured":"Elumalai N.; Berg A.; Rubner S.; Blechschmidt L.; Song C.; Natarajan K.; Matysik J.; Berg T.; Rational development of Stafib-2: A selective, nanomolar inhibitor of the transcription factor STAT5b. Sci Rep 2017,7(1),819","journal-title":"Sci Rep"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41375-017-0005-9","volume":"32","author":"Wingelhofer B.","year":"2018","unstructured":"Wingelhofer B.; Maurer B.; Heyes E.C.; Cumaraswamy A.A.; Berger-Becvar A.; de Araujo E.D.; Orlova A.; Freund P.; Ruge F.; Park J.; Tin G.; Ahmar S.; Lardeau C.H.; Sadovnik I.; Bajusz D.; Keser\u0171 G.M.; Grebien F.; Kubicek S.; Valent P.; Gunning P.T.; Moriggl R.; Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia 2018,32(5),1135-1146","journal-title":"Leukemia"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fonc.2019.00048","volume":"9","author":"Loh C-Y.","year":"2019","unstructured":"Loh C-Y.; Arya A.; Naema A.F.; Wong W.F.; Sethi G.; Looi C.Y.; Signal Transducer and Activator of Transcription (STATs) proteins in cancer and inflammation: Functions and therapeutic implication. Front Oncol 2019,9,48","journal-title":"Front Oncol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/cncr.30490","volume":"123","author":"Rousselot P.","year":"2017","unstructured":"Rousselot P.; Prost S.; Guilhot J.; Roy L.; Etienne G.; Legros L.; Charbonnier A.; Coiteux V.; Cony-Makhoul P.; Huguet F.; Cayssials E.; Cayuela J.M.; Relouzat F.; Delord M.; Bruzzoni-Giovanelli H.; Morisset L.; Mahon F.X.; Guilhot F.; Leboulch P.; French C.M.L.; Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study. Cancer French CML Group2017,123(10),1791-1799","journal-title":"Cancer"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"96710","DOI":"10.18632\/oncotarget.18073","volume":"8","author":"Bartalucci N.","year":"2017","unstructured":"Bartalucci N.; Calabresi L.; Balliu M.; Martinelli S.; Rossi M.C.; Villeval J.L.; Annunziato F.; Guglielmelli P.; Vannucchi A.M.; Inhibitors of the PI3K\/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A\/CIP2A axis. Oncotarget 2017,8(57),96710-96724","journal-title":"Oncotarget"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1111\/bcp.13260","volume":"83","author":"Duong J.K.","year":"2017","unstructured":"Duong J.K.; Griffin M.J.; Hargrave D.; Vormoor J.; Edwards D.; Boddy A.V.; A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia. Br J Clin Pharmacol 2017,83(8),1713-1722","journal-title":"Br J Clin Pharmacol"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/174769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T11:51:09Z","timestamp":1582631469000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/174769\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":104,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,1,24]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520619666190906160848","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}